HAVCR2 and colorectal carcinoma: In CRC, targeting LAG-3 or TIM-3 in combination with PD-1 or CTLA-4 blockade could potentially synergize to overcome Treg-mediated immunosuppression, thereby enhancing antitumor immunity (86, 93).